Stavudine induced lactic acidosis, risk factors and predictive laboratory markers : a nested case-control study in South Africa. by Luke, Christopher Alan.
 
Stavudine induced lactic acidosis, risk factors and predictive 
laboratory markers: A nested case-control study in South Africa  
 
 
Ref no: HIV002/07 
 
Submitted to:  
NELSON R. MANDELA SCHOOL OF MEDICINE 




Submitted in partial fulfilment of the academic requirements for the degree:  
Master of Family medicine  
 (The dissertation contributes 25% of the Mfam med qualification)   
 
BY  
Dr. Christopher Alan Luke, student number 204524979 
 
SUPERVISOR 
Professor Mahomed-Yunus S. Moosa 
 
November 2012 






The incidence of antiretroviral therapy induced lactic acidosis and its associated mortality 
may be reduced by appropriate dosing, risk stratification and early detection. This study 
describes the epidemiology, risk factors and predictive laboratory markers for lactic 
acidosis in subjects commenced on stavudine containing antiretroviral therapy between 
2004 and 2007 at a hospital in KwaZulu- Natal. Persons with body weight above 60kg 
received 40mg twice daily and those below 30mg. 
Methods 
A nested case-control study design was used. Risk factor analysis was adjusted for the 
established risk factors of weight and gender. 
Results 
Lactic acidosis occurred in 79 (17 per 1000 person years) of 1 762 persons. Significant 
baseline risk factors were female gender (Adjusted Odds Ratio (AOR) =5.4) and 
increased body weight (AOR, compared to persons <60 kg, was 6.6 for persons 60 to 69 
kg, 6.9 for persons 71 to 80 kg, and 95.7 for persons >80 kg). Predictors six months into 
therapy were an alanine transaminase >50 IU /L (AOR=11.1) and triglyceride between 1-
1.5 mmol/l (AOR=11.2 compared to persons with triglyceride <0.5 mmol/l). No 
associations were found with regard to age, CD4 counts, viral loads or creatinine and 
albumin levels. 
Conclusion 
Obese females are at greatest risk for lactic acidosis with exponential increased in risk at 
weights above 80kg. The 30mg dose may be preferable, given that a sharp increase in 
risk occurred at 60kg, and that that the 30mg dose has been shown to have adequate 
virologic suppression. Additional risk factors for LA include an increase in alanine 
transaminase and triglyceride at 6 months of treatment. 
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ACRONYMS AND ABBREVIATIONS 
 
ALT: Alananine transaminase  
ART: Antiretroviral therapy 
HIV: Human immunodeficiency virus  
KZN: KwaZulu- Natal 
LA: Lactic acidosis 
NRTI: Nucleoside reverse transcriptase inhibitors 
pyrs: Person years of observation 
SA: South Africa  
SHL: Symptomatic hyperlacataaemia 
TRIG: Triglyceride 
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CHAPTER 1: LITERATURE REVIEW 
1.1 INTRODUCTION 
South Africa (SA) has one of the highest HIV prevalence globally (11% in 2008) with KwaZulu-Natal 
(KZN) the worst affected province (16%)(1). Limiting drug toxicity, in the context of a limited 
formulary, is a major challenge (2).  
 
A number of reports of from SA in 2006 and 2007 described a higher than expected incidence of ART 
induced lactic acidosis (LA) (3, 4, 5) attributed to stavudine. This is of particular concern given the 
associated mortality (6).  
 
Here we describe the epidemiology, clinical presentation and risk factors associated with LA. In 
addition we explored early warning markers for LA.  
1.2  BACKGROUND 
1.2.1 Incidence of LA  
In the developed world LA is reported to occur at an incidence rate of 0.6 to 10 per 1000 person years 
exposure to ART (6, 7). In developing countries LA has been reported to occur at an incidence rate of 
11 to 19/1000pyrs (2, 4, 8) on stavudine based therapy. 
1.2.2 Mechanism of NRTI induced LA 
Nucleoside reverse transcriptase inhibitors (NRTIs), by inhibiting the mitochondrial DNA polymerase 
γ enzyme cause mitochondrial dysfunction (6, 9, 10). This forms the basis for several of the toxic 
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effects, namely; LA, asymptomatic and symptomatic hyperlactatemia (SHL), peripheral neuropathy, 
lipodystrophy, hepatic steatosis and pancreatitis (10, 11, 12, 13).  
 
The risk for LA is not equal across all NRTIs. Effect is greatest with didanosine (DDI) which is > 
stavudine (D4T) > zidovudine (AZT) > abacavir (ABC) = lamivudine (3TC) = tenofovir (TNF) (14, 
15). 
1.2.3 Clinical features of NRTI induced LA 
The majority of patients (75%) experience weight loss (4, 16). Loss of appetite (63%) is also common 
(4). Other symptoms include fatigue, myalgia, abdominal pain, abdominal distension, nausea, vomiting, 
weakness or dyspnoea (7, 12, 17). Patients generally present with a partially compensated high anion 
gap metabolic acidosis with a lactate that is characteristically greater than 5mmol/L (12). The 
symptoms of LA begin several months before the diagnosis is made (7, 17). 
 
Not surprisingly several studies have found other manifestation of mitochondrial toxicity, such as 
peripheral neuropathy (4, 16, 17), lipodystrophy (17, 18, 19,) and liver abnormalities to be associated 
with LA (6, 16, 12, 17). Thus presentation with one form of toxicity should alert the clinician to the 
possibility of others.  
 
LA is the most serious of the toxic effects with a case fatality of 33% to 60% (6, 7, 20). Serum lactate 
levels greater than ten are associated with a mortality of around 80% (17, 21). Lower body weight and 
higher alanine transaminase (ALT) has also been associated with higher mortality (21). The lower 
mortality reported in more recent studies (21-30% (4, 5, 16)) may be explained by increased clinician 
awareness resulting in earlier diagnosis (6, 22). 
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Lactic acidosis has been reported to occur from one to 20 months of treatment (7). The majority of 
patients present six to 17 months from ART initiation (4, 16). Median time to presentation is eight to 
ten months (4, 5, 16).  
1.2.4 The relationship between LA and liver abnormalities 
Hepatic abnormalities are a common finding at presentation of LA. These manifest as a tender 
hepatomegaly and mild elevations in ALT (16) in up to 65% of patients (8). Jaundice is rarely seen. 
Hepatic steatosis has been documented on imaging studies with histologic finds of necrosis in more 
fulminant cases (6, 12, 17).  
 
The relationship between the liver abnormalities and LA is poorly understood (6). It is thought that 
both LA and hepatic steatosis have a common pathogenesis, via mitochondrial toxicity (6, 23). 
However, hepatic steatosis and steatohepatitis could affect the livers ability to metabolise lactate thus 
contributing to LA (6, 24, 25). This latter theory is supported by the fact that a strong association has 
been shown between LA and obesity (4, 5, 16), and that underlying hepatic steatosis is common in 
obese persons (26). In addition, the mechanism by which hypertrigylcerideamia, hyperglycemia and 
viral hepatitis may predispose to LA might be hepatic steatosis and steatohepatitis (27).  
1.2.5 Early warning markers for LA  
Elevation of lactate levels has been shown to be common during treatment with NRTIs, and does not 
reliably predict LA (11, 28, 17). To impact on the high mortality associated with LA it is imperative to 
find alternate ways to predict or diagnose LA (17). 
1.2.6 Definition of LA 
There is no universally accepted definition of ART induced LA (17). Most definitions include a lactate 
greater than 5mmol/L with the standard serum bicarbonate less than 20mmol/L (5, 16, 29, 17, 15). 
Some also include a Ph <7.34 (30) and a high anion gap. A universal requirement is the exclusion of all 
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other causes of LA. Conditions that should be excluded include; recent exercise, sepsis, diabetic 
ketoacidosis, biguanide therapy, renal disease, liver disease, malignancy and hypo perfusion states (12). 
1.2.7 Lactic Acidosis and Symptomatic Hyperlactatemia  
Patients with SHL present with symptoms similar to those with LA except that they are not acidotic 
and generally have lower lactate levels (12). There is no set definition for SHL, which has contributed 
to the wide variation in incidence reported in the literature (6, 12). SHL and LA are likely to be 
different manifestations of the same pathogenic process with each being different ends of the same 
spectrum of illness, with SHL likely preceding LA (12). Risk factors for the development of SHL are 
therefore likely to be the same as that for the development of LA. The incidence of SHL in developed 
countries varies from 3,5 to 20/1000 pyrs of ART (6, 11, 22) compared to 17,5 to 36/1000pyrs (4, 8, 
31) reported in developing countries, with stavudine the main culprit. 
1.2.8 Treatment options 
Treatment is mainly supportive with discontinuation of the offending agent, and intravenous fluids 
(12). In patients with decompensated acidosis bicarbonate infusion is often given however, there is no 
evidence to support its use (12). In severe cases bicarbonate dialysis and respiratory support is often 
offered. No studies have shown any specific therapy to be effective beyond general supportive care 
(12). AZT has been shown to be safe when rechallenging patients with NRTIs (4, 15, 17). 
1.3 RISK FACTORS FOR LA 
Many possible risk factors for LA (discussed further and referenced below) have been identified 
including; female gender, pregnancy, advanced age, impaired renal or liver function, regimens 
containing efavirenz, co-infection with hepatitis B, increased weight or BMI, diabetes, low CD4 
counts, good adherence to ART, low serum albumin, dyslipidaemias and hyperglycemia.  
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Risk factors will be considered in two groups; baseline risk factors (factors that predict increased an 
risk of LA at commencement of ART) and evolving risk factors (factors that emerge while on 
treatment).  
1.3.1 Baseline risk factors 
Female gender has been well established as a strong risk factor for LA (2, 3, 4, 5, 6, 8, 16, 29, 32). LA 
is estimated to occur up to 10 times more commonly in females than males (3, 4, 5, 8, 31).   
 
Excess weight (or high body mass index) has also been convincingly shown to be a risk factor for LA 
(2, 3, 4, 5, 8, 16, 32, 36). The risk continues to increase as the weight increases (2, 16). Osler et al 
showed an adjusted odds ratio of five for weight > 60kg compared to 19 for weight > 75kg (16). 
Mathews et al showed an additional three fold increase in risk for every 30% increase in BMI (2).  
 
Stavudine induced LA appears to be dose dependent. This is supported by the fact that higher doses 
have been associated with greater mitochondrial toxicity in vivo (33). Higher doses have also been 
shown to cause an increased incidence of other toxicities such as of peripheral neuropathy and 
lipoatrophy (34). However, there are currently no control studies that explored dose as a risk factor for 
LA. It has been suggested that 30mg or even 20mg may be more appropriate since they have equal 
antiviral efficacy to the 40mg dose (34). 
 
There is conflicting evidence regarding advanced age as a risk factor. Age greater then 40yrs. was 
found to be a risk factor for hyperlacateamia in two small cases series (18, 28) and in a case control 
study (30). Age was however not found to be a risk factor in other studies from both high and low 
income settings (2, 3, 4, 5, 8, 9, 16, 29). 
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Diabetes has been suggested as a risk factor based on small studies in the developed world (19, 35). 
There are no controlled studies assessing this as a risk factor. 
 
Pregnancy has been suggested to be a risk factor for LA, based on a number of case reports (6), but 
has not been evaluated in control studies. 
 
There is conflicting evidence regarding low CD4 counts as a risk factor for LA. Small cohorts (18, 36) 
in studies from the developed world demonstrated an association with hyperlactataemia. This was 
supported by two controlled studies in the developing world (2, 30) but not by others (2, 16, 19, 29).  
 
There is also conflicting evidence on impaired renal function as a risk factor for LA. Two studies (2, 
18) found high creatinine levels associated with LA, as opposed to a large control study from the 
developing world (16). 
   
Liver abnormalities have been suggested as risk factors for LA (16). This might be due to the fact that 
stavudine is commonly associated with steatohepatitis (12). 
 
The association between hyperlactatemia and raised cholesterol and triglyceride suggests a possible 
association between lipid abnormalities and LA (18, 19, 35, 37). Lipid levels have not yet been 
assessed for an association with LA in controlled studies.  
 
Efavirenz has been suggested as a risk factor for LA in small case series (38) and a small prospective 
study (29), but not confirmed in a large controlled study (16). 
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1.3.2 Early warning signs of LA after commencing HAART  
Early rapid weight gain in the first 3 months (16) and an increase in ALT (6, 16) while on ART have 
all been associated with the subsequent development of LA. 
  
Based on small cohort studies in the developed world hyperglycemia and hyperlipidaemia have been 
associated with hyperlactatemia (18, 19). These remain to be evaluated in LA. 
1.4 AIMS OF OUR STUDY 
To determine the incidence of stavudine associated adverse events in a local cohort of patients in a 
South African setting with a special focus on risk factors associated with the development of LA. 
1.4.1 Objectives 
1. Determine the incidence of specific stavudine related toxicities that necessitate a drug switch in a 
large antiretroviral rollout programme. 
2. Describe the demographic, clinical and biochemical features of a group of patients that develop LA. 
3. Determine the factors that might predict the development of LA prior to commencement of ART and 
while on ART (early warning signs) and therefore define a category of patients at particular risk for the 
development of LA. 
1.5 OPERATIONAL DEFINITIONS USED IN OUR STUDY 
Lactic acidosis (LA) for the purposes of this study was defined as a patient with symptoms consistent 
with LA (weight loss, abdominal pain or distension, dyspnoea, fatigue, nausea, vomiting), a venous 
lactate ≥ 5 AND a serum standard bicarbonate or CO2 level <20 mmol/L (5, 15, 16, 29). Blood for 
lactate levels had to have been taken without a tourniquet in a tube containing potassium citrate and 
sodium fluoride and kept on ice until processed by the laboratory within 4 hours (12).  
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LA Exclusion criteria (12). Patients with a history of chronic persistent diarrhoea, disseminated TB, 
renal failure, liver failure or malignancy or examination findings suggestive of ketoacidosis (HGT >15 
and ketones on urine analysis), dehydration (defined as BP<110/60 with rapid normalization of lactate 
with fluids or, evidence of systemic sepsis (increased WCC, clinical evidence of organ specific 
infection, or fever) or evidence of malignancy will be excluded (12). 
 
To be considered to have symptomatic hyperlactatemia patients had to have a serum lactate ≥ 2.5 
with symptoms but not meeting the criteria for LA.  
 
Lipodystrophy: asymmetric weight loss or severe breast hypertrophy. 
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2CHAPTER 2: METHODS 
2.1 STUDY DESIGN 
A retrospective cohort is described, followed by a nested LA case-control analysis. 
2.2 STUDY POPULATION AND SETTING 
This study was conducted at Port Shepstone hospital in KwaZulu- Natal, serving a semi-rural 
population. The study population consisted of adult persons (>18yrs) living with HIV with a CD4 
count less than 200 cells/µl or Stage 4 illness (World Health Organization criteria (39)) commenced on 
ART between July 2004 and April 2007, and followed until November 2008. Patients routinely 
received twice-daily stavudine 40 mg if over 60 kg, or 30 mg if less than 60 kg, combined with 
lamivudine and either nevirapine or efavirenz, according to the South African National guidelines (40). 
Zidovudine was substituted for stavudine when severe toxicity occurred.  
  
Port Shepstone hospital has a dedicated onsite ART clinic and pharmacy. All ART patient data were 
routinely captured on a Microsoft access electronic register. Routine blood tests were performed on all 
patients at baseline and after six months of follow-up. All serum analysis were performed at an onsite 
laboratory (utilizing the DXI 800 machine for chemistry and DXI 600 machine for haematology 
investigations), except for viral load estimations, which were sent conducted at a central virology 
laboratory (utilizing the Abbott m2000sprt and Abbot m2000rt machines) Pharmacy routinely captured 
a record of all ART regimen changes due to side effects.  
 
At each visit the ART nurse recorded the patient symptoms and weight. If the patient had signs or 
symptoms of hyperlactateamia (weight loss or any abdominal symptoms) a bedside venous lactate level 
(using the Synchron systems quantitative reagent method) was recorded. This was followed by a formal 
lactate if the bedside lactate reading exceeded 3 mmol/L. Patients with a formal lactate greater than 
four were referred to a doctor for assessment. Patients were assessed by the one of a team of five 
doctors and managed using standard guidelines (12, 19).   
2.3 DESCRIPTION OF THE COHORT  
The relevant cohort for the study was determined using the ART clinic register by selecting patients 
that initiated ART between dates of interest. Data was obtained from the pre-existing ART clinic 
Microsoft access electronic database. Baseline data that had routinely captured on the electronic 
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register included the patient name, age, gender, ART initiation date, weight, CD4 count, haemoglobin 
level, treatment regimen and follow-up dates. Relevant information was obtained using the Microsoft 
access database applying Microsoft software functions. 
2.3.1 Identifying stavudine toxicity cases 
Pharmacy Regimen change records consisted of the motivation forms submitted by the clinician who 
captured the date, the side effect that prompted the regime change, and if the toxicity was related to 
lactate then the lactate level was recorded. The number (n) of patients experiencing a particular side 
effect was determined by counting the number of motivations submitted for regimen change to 
pharmacy for that side effect. 
 
In the case of LA case identification clinical notes were then retrieved to verify the diagnosis and 
collect further data. In addition mortuary records were interrogated to capture additional cases of LA 
that would not have been captured by pharmacy records because a regimen change would not have 
been motivated for, for obvious reasons. All cases of LA identified were subjected to the case 
definition (see section 1.5) by two experienced clinicians to generate a final list of LA cases. 
2.4 DATA CAPTURING FOR LA CASES 
All relevant data from the clinical charts was captured onto a Microsoft Excel spread sheet (for a list 
the of variables collected refer to addenda, section 6.1). All data entry was entered was verified by the 
author. 
2.5 IDENTIFYING CONTROLS 
A list of potential controls was generated using the ART clinic Microsoft access electronic register. For 
each case of LA a control was randomly chosen from a list that matched the case for month of ART 
initiating and duration of treatment with stavudine. Data was collected for controls in the identical 
manner as for LA cases (above).  
2.6 STATISTICAL ANALYSIS: NESTED CASE CONTROL STUDY 
Conditional logistic regression modelling for matched pairs was used to compare the variables at 
baseline and at six months follow up. STATA version 10 software was used by the study 
biostatistician.   
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In the analysis of risk factors, weight and gender as the well established risk factors for LA, were 
controlled for by using statistical methods. The risk factors, duration of therapy and duration of 
exposure were controlled for by the matching of cases and controls. Any additional factors found to be 
significant were controlled for in the assessment of other potential risk factors. A p value of < 0.05 was 
considered significant. 
2.7 EXTERNAL VALIDITY 
Port Shepstone is within the province of greatest HIV prevalence and serves a mix of urban and rural 
indigenous communities, similar to the rest of SA. Thus, the study findings are likely relevant and 
applicable to most ART treatment sites in SA.  
2.8 CONSIDERATION OF BIAS 
Case detection bias was minimized by retrospective evaluation of objective markers (laboratory 
results). Information bias was minimized by use of the same laboratory facilities in the same time 
period for cases and controls. Control selection bias was minimized in the random selection process 
described.  
2.9 ETHICS 
The ethical approval was obtained from the hospital ethics committee and the Biomedical Research 
Ethics Committee of the Nelson R Mandela School of Medicine South Africa. 
 
This was a retrospective chart review, thus Biomedical Research Ethics Committee did not expect us to 
obtain consent from individual patients. The findings would be beneficial to the community as a whole 
and not, in any way, detrimental to the study subjects.  
3CHAPTER 3: RESULTS 
3.1  DESCRIPTION OF THE COHORT 
A total of 1 762 adult patients (mean age 36.1 years, mean baseline CD4 count 113 cells/µl) were 
initiated on stavudine containing ART from August 2004 to April 2007. Follow up continued until 
November 2008 resulted in observation of 4 566person years. The cohort was followed for a mean of 
2.5 and a median 1.5 years.  
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Baseline patient characteristics categorized by gender and weight are shown in Table 1. The majority of 
patients were female. Just under half of the cohort weighed <60 kg.  
 
 
Table 1. Baseline characteristics of adults commenced on stavudine containing ART, between 












Females 1226 69.7% 35.4 60.6 113 11.2 
<60 kg 583 33.7% 35.1 51.2 96 10.8 
60-69 kg 359 20.8% 35.2 64.0 128 11.5 
70-79 kg 117 6.8% 36.2 74.0 125 11.7 
>80 kg 99 5.7% 36.1 88.5 144 12.1 
Weight unknown 68 3.9% 
    Males 536 30.4% 37.8 60.9 114 11.3 
<60 kg 244 14.1% 37.2 51.5 101 11.0 
60-69 kg 164 9.5% 37.9 63.9 113 11.4 
70-79 kg 56 3.2% 38.1 74.0 123 11.5 
>80 kg 40 2.3% 39.6 87.2 154 12.3 
Weight unknown 32 2.0% 
    Total 1762 100% 36.1 60.7 113 11.2 
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3.2 INCIDENCE OF STAVUDINE TOXICITY  
Stavudine induced toxicity requiring a drug substitution occurred in 275 patients giving an incidence 
rate of 60/1000 pyrs.  
LA and SHL were the most common toxicities (Table 2). The incidence of LA in females increased 
sharply at 60kg, and then rose exponentially in subjects with weights above 80kg (table 2). This is 
graphically expressed in graph 1.   
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Table 2.  Cumulative Incidence and Incidence rates of stavudine related toxicities in adults 
commenced on ART between 2004 and 2007 at Port Shepstone Hospital (N=1 762) 
Toxicity type (n)  Total at risk 
 
Incidence 
Incidence rate per 1000 
pyrs (95%CI) 
Lactic acidosis 79 1762 4.5% 17 (14 to 21) 
       Females* 72 1226 5.9% 23 (18 to 28) 
        <40kg 1 24 4.2% 16 (-15to 47) 
        40-59kg 4 175 2.3% 9 (0 to 17) 
        50-60 kg 9 383 2.3% 9 (3 to 15)  
        60-69 kg 26 359 7.2% 28 (18 to 38) 
        70-79 kg 9 117 7.7% 30 (11 to 48) 
        80-89 kg 12 76 15.8% 69 (34 to105) 
        >90kg 9 32 28.1% 109 (48 to 167) 
Kg not recorded 2    
      Males 7 536 1.3% 5 (1 to 9) 
        <60 kg 2 244 0.8% 3 (-1 to 8) 
        60-69 kg 1 164 0.6% 2 (-2 to 7) 
        70-79 kg 2 56 3.6% 14 (-5 to 32) 
        >80 kg 2 40 5.0% 19 (-7 to 46) 
Symptomatic 
hyperlactataemia 
84 1762 4.8% 19 (15 to 22) 
Peripheral 
neuropathy 
67 1762 3.8% 15 (11 to 18) 
Lipodystrophy 43 1762 2.4% 9 (7 to 12) 
Pancreatitis 2 1762 0.1% 0 (0 to1) 




3.3 SPECTRUM OF CLINICAL PRESENTATION OF LA  
Of the 63 LA cases with complete records 59 (94%) presented with loss of weight (median loss of 6 kg, 
inter quartile range 4 to 8 kg), 45 (71%) with abdominal symptoms (nausea, anorexia, pain or 
distension), 15 (24%) with peripheral oedema and 8 (11%) with dyspnoea. Peripheral neuropathy was 
recorded in 44 (56%) cases and lipodystrophy in 35 (42%). Loss of weight was the only presenting 
symptom in 13 (21%) cases. A combination of loss of weight and abdominal symptoms occurred in 43 
(68%) cases. LA occurred between eight and 16 months treatment duration in the majority (67/79) of 
cases (median 10 months, range 5 to 24 months).   
Of the 79 LA cases the median serum lactate was 7.5 mmol/l (range 5.0 to 11.7) and mean serum CO2 
17 (range zero to 19). 21 cases (27%) were severe, lactate >10 mmol/l or serum CO2 <15 mmol/l. In a 
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subgroup of 65 LA cases in which a blood gas analysis had been performed, 49 (75%) had a pH <7.34 
and 11 (17%) a pH<7.2.  
The overall mortality from LA was 7.6% (6/79). All cases that died had a lactate of >10 mmol/L. Of 
the patients with lactate >10 forty percent (6/15) died.  Seventy five percent (6/8) cases with a serum 
CO2 <15 mmol died. All cases with serum CO2 <10 mmol/l died. Fifty five percent (6/11) patients 
with pH <7.2 and 83% (5/ 6) with a pH<7.1 died. Four cases of LA occurred during pregnancy. All of 
these patients survived. 3 pregnancies were carried to term with babies were born alive and well. There 
was one intrauterine death.  
All patients with stavudine toxicity were changed from stavudine to zidovudine without recurrence of 
lactic acidosis during the follow up period. 
3.4 COMPARISON BETWEEN LA CASES AND CONTROLS AT 
BASELINE 
 The clinical characteristics of cases with LA and controls were compared at baseline (Table 3). Female 










Table 3. Baseline characteristics of LA cases and controls at Port Shepstone hospital between 
2004 and 2007 (n=79) 
* Only pairs with results were included in the analysis 
†Mean values 
‡ McNemar’s chi square test could not be computed due to low numbers; Conditional logistic regression model could not be 
achieved due to small sample size 
  Analysis of matched pairs adjusted for gender 
and weight 
 Characteristic 
Cases  controls   n* p value AOR (95% CI) 
Age (years)† 35.8 35.9 70 0.929 1.0 (0.9 to 1.1) 
Female gender 91.1% 70.5% 70 0.006 5.3 (1.6 to 17.8) 
Efavirenz regimen 51.8% 53.2% 70 0.881 0.9 (0.3 to 2.6) 
Previous ARVs 12.7%% 6.3% 70 0.371 0.7 (0.3 to 1.5) 
Diabetes 3.8%% 1.3% 69 0.625 ‡ 
Currently pregnant 5.1% 0.0% 68 ‡ ‡ 
Hepatitis B surface 
antigen positive 
9.1% 12.2% 16 0.883 1.1 (0.3 to 4.4) 
Weight (kg)† 70.2 57.0 69 0.001 1.1 (1.1 to 1.2) 
<60kg     Reference (1) 
60-70 kg    0.006 6.6 (1.7 to 25.0) 
71-80 kg    0.018 6.9 (1.4 to 34.3) 
>80 kg    0.001 95.5 (6.9 to 1318.4) 
 CD4 (cells/µL)† 126 113 70 0.677 1.0 (1.0 to 1.0) 
Viral load 
(copies/ml)† 
167850 1812968 29 0.446 1.0 (1.0 to 1.0) 
Haemoglobin (g/dl)† 11.3 11.3 66 0.167 0.9 (0.7  to 1.0) 
Alanine 
transaminase (iu/l)†  
30 26 60 0.511 1.0 (0.9 to 1.0) 
Albumin  (g/l)†  34 32 56 0.338 0.9 (0.90 to 1.0) 
Urea (mmol/l)† 3.52 3.69 54 0.353 1.1 (0.89to 1.5) 
Creatinine †(µmol/l) 81 77 54 0.954 1.0 (0.9 to 1.0)  
Cholesterol † 
(mmol/l) 
3.6 3.6 52 0.919 0.9 (0.6 to 1.7) 
Triglycerides† 
(mmol/l) 
1.3 1.2 52 0.125 1.7 (0.9 to 3.3) 
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3.5 COMPARISON OF CASES AND CONTROLS SIX MONTHS INTO ART 
See table 4 for comparison of clinical variables between cases and controls six months into ART. A 
higher ALT or TRIG was significantly associated with LA. There was no correlation between the ALT 
and TRIG (Spearmen Correlation Coefficient = 0.083, p=0.372).  
Table 4. Comparison of selected parameters between LA cases and controls six months into ART, 
at Port Shepstone hospital between 2004 and 2007 (n=79) 
 Description of groups Analysis of matched pairs adjusted for 






Controls  n*     P value AOR (95% CI) 
 CD4  (cells/ul)† 253 267 56 0.220 1.0 (1.0 to 1.0) 
Log Viral load)† 
(copies/ml)† 
630 18096 47 0.488§ 1.0 (1.0 to1.0) 
Haemaglobin (g/dl)†  12.9 13.3 57 0.221 0.8 (0.6 to 1.1) 
Alanine tranaminase 
(IU/L)† 
44 33 52 0.029 1.0 (1.0 to 1.1) 
    >50IU/l 30.2% 9.2%  0.015 11.1 (1.6 to 77.7) 
Urea (mmol/L)† 3.5 3.6 55 0.828 1.1 (0.7 to 1.6) 
Creatinine (umol/L) † 74 73 55 0.806 1.0 (1.0 to 1.0) 
Cholesterol †(mmol/L) 4.5 4.2 51 0.111 1.6 (0.9 to 2.8) 
Triglycerides (mmol/l)† 1.41 0.88 52 0.039 8.7 (1.1 to 67.1) 
      <=0.5 
       0.5-1 
       1.1-1.5 















3.9 (0.7 to 21.3) 
11.2 (1.1 to118.6) 
4.9 (0.2 to 103.2)  
* Only matched pairs with results were included in the analysis 
†Mean values 
§ Log value used in analysis 
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3.6 COMPARISON OF THE CHANGE IN SELECETED PARAMETERS 
BETWEEN CASES AND CONTROLSINTHEFIRST SIX MONTHSOF ARTY 
Changes in clinical parameters over 6 months of ART are compared between cases and controls in 
Table 5. An increase in TRIG, compared to a decrease in controls was nearly found to be significant 
(p=0.065). 
Table 5. Comparison of the median/mean change in characteristics in LA cases and controls over 
first six months of ART, at Port Shepstone hospital between 2004 and 2007 (n=79) 
 Cases  Controls 
Analysis of  Matched pairs adjusted for gender 
and weight 
n P value AOR (95% CI) 
Weight (kg) 4 5 63 0.088 1.1 (1.0 to 1.2) 
CD4  (cells/ul) 102 153 56 0.319 1.0 (1.0 to 1.0) 
Viral load 
(copies/ml) 
167220 1794872 20 0.753 1.0 (1.0 to 1.0) 
Hb (g/dL) 1 2 52 0.614 1.0 (0.8 to 1.1) 
ALT (IU/L)  14 6 39 0.306 1.0 (1.0 to 1.1) 
By >20iu/l    0.758 1.5 (0.1 to 24.3) 
Urea (mmol/l) 0.02 0.09 45 0.561 0.9 (0.7 to 1.2) 
Creatinine 
(umol/l) 
-7 -4 45 0.853 1.0 (1.0 to 1.0) 
Cholesterol 
(mmol/l) 
1.4 0.6 42 0.149 2.2 (0.8 to 6.2) 
Triglycerides 
(mmol/l) 
0.11 -0.33 44 0.065 1.4 (1.0 to 2.1) 
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4CHAPTER 4: DISCUSSION 
This study was inspired by the large number of reports (2, 3, 4,5) of toxicity associated with anti-
retroviral treatment, following the rollout of ART on a massive scale by the national department of 
health in SA. The drug most implicated was stavudine (2, 3, 4, 5). Here we describe the epidemiology, 
incidence, clinical presentation and risk factors associated with LA and go further to explore 
biochemical markers that are potential predictors of LA. 
4.1 INCIDENCE OF STAVUDINE TOXICITY 
The incidence rate of LA (17/1000 pyrs) is higher in our cohort compared to the developed world (0.6-
10/1000 pyrs) (6, 7). This is consistent with other local SA cohorts (4, 5, 8, 31). 
 
The incidence of SHL (19/1000 pyrs) in our cohort is in the upper range reported in the developed 
world (3,5 to 20/1000 pyrs (6, 11, 22) and is similar to other local cohorts (4, 5, 8, 31). This is difficult 
to comment on due to the lack of a standardized definition for SHL (6, 12). 
 
The incidence of lipodystrophy and peripheral neuropathy that warranted discontinuation of 
stavudine (9/1000 pyrs and 3.8/1000pyrs respectively) found in our cohort is lower than other local 
cohorts (3, 8). This may be due to the shorter duration of observation in our cohort, median of 18 
months compared to 3 years (3, 8) and that peripheral neuropathy and lipodystrophy are late side 
effects (24).   
4.2 POTENTIAL BASELINE RISK FACTORS FOR LA 
Female gender and increased body weight have been clearly associated with LA (2, 16). Our study 
again confirms female gender as a strong risk factor. The risk in females (incidence rate of 23/1000 
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pyrs) in our cohort, similar to other local studies (2), was about five times that in males (incidence rate 
of 5/1000 pyrs). The high incidence of LA in SA may be explained by the high dominance of females 
in SA cohorts (3, 4, 5) and also the high prevalence of female obesity in SA (41). 
 
Our study also confirms excess weight as a strong risk factor for LA (2, 16, 32). The relationship 
between weight and LA, particularly in females, appears to be complex. A dramatic increase in 
incidence (Table 2, fig 1) and risk (Table 3) is observed when baseline weight exceeded 60kg, followed 
by a second exponential increase with baseline weights above 80kg. One might postulate that the 
increase in incidence with weights >60kg is due to the higher dose of stavudine recommended for this 
weight (16) keeping in mind that mitochondrial toxicity are dose related (33). However, the exponential 
increase in risk above 80kg is likely due to other factors. Interestingly we demonstrate that female 
patients <60kg who received 30mg stavudine also had a high incidence of LA relative to reports from 
the developed world. This suggests that further dose reductions should be considered to reduce the risk 
of LA. Clearly such a strategy will have to be balanced against the anti-viral potency of lower doses.     
 
Diabetics and pregnancy are considered risk factors for LA. This risk might be related to weight. Due 
to small number of patients with these conditions we were unable to evaluate these risks. 
 
The lack of association between CD4 counts and LA here is consistent with other similar case control 
studies (16, 29). This is in contrast to the finding of Mathews et al (2) and others (30). Possible 
explanations include study design issues and under-representation of subjects with higher CD4 counts 
in our cohort due to criteria for ART initiation in SA (40).   
 
Age, baseline albumin, renal function, liver transaminase levels, lipid levels and HBV infection was not 
associated with LA in this study. This was consistent with some studies but contrary to others (2, 16).  
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4.3 PREDICTIVE LABORATORY MARKERS AFTER SIX MONTHS  
Since most cases of LA occur 6 to 18 months into ART (5, 16), we considered factors at the six months 
time point that may serve as predictors of LA.  
We showed that an elevated ALT >50 IU/L six months into ART predicted increased risk for LA 
(Table 4). This finding was not unique to our study (16). The raised ALT may represent significant 
mitochondrial dysfunction manifesting as steatohepatitis.  
Higher triglyceride levels at the six months time point (Table 4) also predicted higher risk for LA. An 
increase in TRIG value over six months was also nearly found to be nearly significant (Table 5). This is 
the first study to assess this as a possible risk factor for LA. The finding is not entirely unexpected if 
one considers that elevated TRIG levels have been previously associated with hyperlactataemia (18, 
19).  There was no correlation between the increase in ALT and TRIG levels, suggesting it is an 
independent predictor of risk. The risk may be related to the association between high TRIG and 
hepatic steatosis (metabolic syndrome), a common (possibly etiologic) feature of LA (refer to chapter 
1, liver abnormalities and LA). The significance is difficult to interpret clinically, as the highest risk 
was for a TRIG in the upper normal range and became less, although still present, at values above this. 
This needs further investigation. 
The actual, or change in, CD4 count and viral load at 6 months has been implicated as a predictor of 
LA by some (2,16). This was not supported by our study, which is consistent with others (16). 
4.4 PRESENTING FEATURES OF LA CASES 
Clinical features of LA including; loss of weight (94% in our cohort), abdominal symptoms (71%) and 
the presence of other stavudine related toxicities such as peripheral neuropathy (56%) and 
lipodystrophy (42%) supports claims made by others (12, 16) that these are useful indicators of LA.  
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As observed by others the majority of patients presented between 8 and 16 months on treatment (range 
5 to 24 months, median 10 months) are consistent with that of other studies (5, 16).  
4.5 MORTALITY AND EARLY LA CASE IDENTIFICATION 
The mortality in this study was unusually low compared to similar large cases control studies (5, 16). 
This may be due to enhanced clinical vigilance, with earlier detection of LA cases following the report 
of a high incidence of LA in 2005 and 2006 (3, 5). Patients with loss of weight loss were routinely 
screened for LA from 2006 onwards at PSH. This is supported by the fact that most patients LA cases 
had lactate levels less than 10. 
 
The associations of mortality, such as the level of lactate and severity of metabolic disturbance (17, 21) 
at presentation, were also observed here.   
4.6 RECOMMENCEMENT OF ART 
Our study confirmed zidovudine as a safe alternative (4, 15, 17).  Tenofovir is probably an even better 
alternative, given that it has even lower association with LA (42).  
4.7 STUDY LIMITATIONS 
Being a retrospective study we had to contend with incomplete record keeping.  
A small number of patients (5%) did not have baseline weights captured on the electronic database, and 
were therefore reported as unknown (Table 1). Due to the small number they had a negligible effect on 
the calculation of incidence according to weight bands (Table 2). Incomplete chart records were also 
noted.  
Blood results were incomplete in both the case and control group.  
Another limitation is that BMI could not be calculated since heights were not measured. 
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5CHAPTER 5: CONCLUSIONS AND RECOMMENDATIONS 
5.1 CONCLUSIONS AND RECOMMENDATIONS FOR CLINICAL CARE 
Clinical presentation is non-specific and requires a high index of suspicion. Timing of presentation and 
presence of other stavudine related toxicities are useful pointers to the diagnosis of LA. 
This study provides supports the WHO guideline revision in 2006, recommending the reduction in dose 
of  stavudine from 40mg to 30mg irrespective of weight (43). It also supports the WHO revision in 
2010, to prefer the use of zidovudine or tenofovir in first line regimens (44), and the SA National 
guideline decision to replace stavudine with tenofovir, in the first line regimen in 2010 (45). 
Female gender and excess weight are the main risk factors. Diabetes and pregnancy were not confirmed 
as risk factors in this study due to the low numbers. Stavudine should be used with extreme caution and 
with close monitoring, if at all.  
Patients with raised ALT or TRIG levels at 6 months into ART should be carefully observed for 
development of LA. A strategy worth considering in such patients would be to commence regular 
lactate screening.  
5.2 RECOMMENDATION FOR FURTHER STUDY 
The incidence of LA and other stavudine toxicities needs to be evaluated at the 30mg dose, particularly 
in higher risk groups. The correct dose of stavudine needs further evaluation, given that 20mg has been 
suggested to provide adequate antiviral efficacy (34). 
ALT and TRIG levels at the 6 months time point, as a predictor of LA needs, further evaluation.   
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APPENDIX 
VARIABLES CAPTURED FOR LA CASES  
Baseline variables: ART initiation date, LA diagnosis date, NNRTI regimen (efavirenz / neviripine), 
age, gender (m/f), diabetes (y/n), pregnant (y/n), already on ART (y/n), weight, CD4 count, viral load, 
urea, creatinine, triglyceride, cholesterol, ALT and albumin levels. 
 
Variables at the six months follow up visit: weight, CD4 count, viral load, urea, creatinine, 
triglyceride, cholesterol, ALT and albumin levels. 
 
Data captured at time of LA diagnosis: date, duration of therapy, change in weight over last 4 
months (kg), specific symptoms recorded in the clinical notes with regards to nausea (y/n), abdominal 
pain (y/n), abdominal distension (y/n), lipodystrophy (y/n), peripheral neuropathy (y/n), loss of appetite 
(y/n) and dyspnoea (y/n) or death (y/n). Biochemical features captured included; formal venous lactate, 
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